Kura Oncology Identifies Farnesylated Proteins Associated with CXCL12 Expression, Potential Biomarker of Clinical Benefit from Tipifarnib in Lymphoma Indications
Kura Oncology, Inc. (KURA)
Last kura oncology, inc. earnings: 2/25 04:03 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.kuraoncology.com/investor-relations
Company Research
Source: GlobeNewswire
– Tipifarnib is a farnesyl transferase inhibitor that downregulates CXCL12 – – Gene expression of the exclusively farnesylated RHOE and PRICKLE2 proteins associated with CXCL12 expression – – Pre-treatment tumor CXCL12 expression identified as a potential biomarker of clinical benefit in patients with DLBCL and CTCL – – CXCL12 pathway biomarkers could enable multiple registrational strategies for tipifarnib – SAN DIEGO, April 02, 2019 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for oncology, reported new findings regarding the mechanism of action of the Company’s lead drug candidate tipifarnib and its potential clinical applications. These findings are being presented today at the American Association for Cancer Research (AACR) Annual Meeting 2019 in Atlanta. A copy of the poster is available on Kura's website at www.kuraoncology.com. Tipifarnib is a potent and selective far
Show less
Read more
Impact Snapshot
Event Time:
KURA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
KURA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
KURA alerts
High impacting Kura Oncology, Inc. news events
Weekly update
A roundup of the hottest topics
KURA
News
- 2 Incredible Growth Stocks to Buy Hand Over Fist [Yahoo! Finance]Yahoo! Finance
- Kura Oncology to Participate in Bank of America Securities Healthcare Conference [Yahoo! Finance]Yahoo! Finance
- Kura Oncology to Participate in Bank of America Securities Healthcare ConferenceGlobeNewswire
- Kura Oncology, Inc. (NASDAQ: KURA) had its "market outperform" rating re-affirmed by analysts at JMP Securities. They now have a $32.00 price target on the stock.MarketBeat
- Kura Oncology, Inc. (NASDAQ:KURA) Q1 2024 Earnings Call Transcript [Yahoo! Finance]Yahoo! Finance
KURA
Earnings
- 5/2/24 - Miss
KURA
Sec Filings
- 5/2/24 - Form SC
- 5/2/24 - Form 10-Q
- 5/2/24 - Form 8-K
- KURA's page on the SEC website